Brookstone Capital Management Has $35.35 Million Stock Holdings in Eli Lilly and Company $LLY

Brookstone Capital Management increased its holdings in Eli Lilly and Company (NYSE:LLY - Free Report) by 10.9% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 46,325 shares of the company's stock after purchasing an additional 4,558 shares during the quarter. Brookstone Capital Management's holdings in Eli Lilly and Company were worth $35,346,000 at the end of the most recent reporting period.Get Eli Lilly and Company alerts:Sector Rotation: 2 Smart Money Moves for 2026A number of other hedge funds have also recently added to or reduced their stakes in the company. Wealth Preservation Advisors LLC bought a new stake in shares of Eli Lilly and Company in the 1st quarter worth approximately $27,000. Sumitomo Mitsui Financial Group Inc. bought a new stake in Eli Lilly and Company in the second quarter valued at $27,000. Evolution Wealth Management Inc. purchased a new stake in Eli Lilly and Company in the second quarter worth about $29,000. Steph & Co. lifted its stake in shares of Eli Lilly and Company by 290.0% in the third quarter. Steph & Co. now owns 39 shares of the company's stock worth $30,000 after buying an additional 29 shares in the last quarter. Finally, Financial Gravity Companies Inc. bought a new stake in shares of Eli Lilly and Company in the second quarter worth $31,000. Institutional investors and hedge funds own 82.53% of the company's stock. Eli Lilly and Company Stock Up 0.5%Shares of NYSE:LLY opened at $1,077.06 on Friday. The company's fifty day moving average is $981.27 and its two-hundred day moving average is $839.03. Eli Lilly and Company has a 1-year low of $623.78 and a 1-year high of $1,111.99. The stock has a market capitalization of $1.02 trillion, a price-to-earnings ratio of 52.69, a price-to-earnings-growth ratio of 1.09 and a beta of 0.37. The company has a debt-to-equity ratio of 1.71, a quick ratio of 1.24 and a current ratio of 1.55. 3 Healthcare Giants Just Raised Dividends—Here’s Who Pays the MostEli Lilly and Company (NYSE:LLY - Get Free Report) last issued its earnings results on Thursday, October 30th. The company reported $7.02 earnings per share for the quarter, topping analysts' consensus estimates of $6.42 by $0.60. Eli Lilly and Company had a net margin of 30.99% and a return on equity of 109.52%. The firm had revenue of $17.60 billion during the quarter, compared to analysts' expectations of $16.09 billion. During the same period last year, the firm posted $1.18 earnings per share. The firm's revenue for the quarter was up 53.9% compared to the same quarter last year. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. Equities analysts anticipate that Eli Lilly and Company will post 23.48 EPS for the current year. Eli Lilly and Company Increases DividendThe business also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 10th. Investors of record on Friday, February 13th will be given a $1.73 dividend. This is a boost from Eli Lilly and Company's previous quarterly dividend of $1.50. The ex-dividend date is Friday, February 13th. This represents a $6.92 annualized dividend and a yield of 0.6%. Eli Lilly and Company's dividend payout ratio is presently 29.35%. Analyst Ratings ChangesPfizer Adds to Its Big Bet on Weight Loss DrugsLLY has been the subject of several research analyst reports. Sanford C. Bernstein reaffirmed an "outperform" rating on shares of Eli Lilly and Company in a research note on Friday, December 19th. JPMorgan Chase & Co. lifted their price objective on shares of Eli Lilly and Company from $1,050.00 to $1,150.00 and gave the company an "overweight" rating in a research note on Tuesday, November 18th. Truist Financial increased their price objective on shares of Eli Lilly and Company from $1,038.00 to $1,182.00 and gave the company a "buy" rating in a report on Wednesday, November 19th. Loop Capital set a $950.00 price target on shares of Eli Lilly and Company in a research report on Monday, November 10th. Finally, Daiwa America upgraded Eli Lilly and Company from a "hold" rating to a "strong-buy" rating in a research note on Tuesday, December 16th. Four research analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and five have issued a Hold rating to the company's stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $1,155.36.Read Our Latest Report on LLYEli Lilly and Company Company Profile (Free Report)Eli Lilly and Company NYSE: LLY is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.See AlsoFive stocks we like better than Eli Lilly and CompanyPut $1,000 into this stock by Jan 1 [Not NVDA]Turn your "dead money" into $306+ monthly (starting this month)Washington prepares for warStrange Crystal Metal Outperforms Silicon Up to 100X33,000% boom from weird new “AI Fuel?”Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.Should You Invest $1,000 in Eli Lilly and Company Right Now?Before you consider Eli Lilly and Company, you'll want to hear this.MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eli Lilly and Company wasn't on the list.While Eli Lilly and Company currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.View The Five Stocks Here